Combination Therapy With Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML

Source: 2021 American Society of Hematology Annual Meeting*
Download Slideset
December 11-14, 2021; Atlanta, Georgia
The combination of azacitidine, venetoclax, and magrolimab demonstrated high response rates with a manageable safety profile in venetoclax-naive patients with newly diagnosed or relapsed/refractory AML.
Format: Microsoft PowerPoint (.ppt)
File Size: 489 KB
Released: December 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings